Therefore, in T1D, C646 treatment should activate insulin signaling through increasing the tyrosine kinase activity of IRβ and promoting the affinity of IRβ to IRS, leading to the activation of insulin signaling and suppression of liver glucose production. This evidence concerns the gene INS and type 1 diabetes mellitus.